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Background
Onchocerciasis is a filarial disease caused by infection with Onchocerca volvulus, a vector-borne parasitic nematode transmitted via the bites of several Simulium blackfly species. In sub-Saharan Africa (SSA), where 99% of the cases occur, the main vectors belong to the Simulium damnosum sensu lato species complex. Modelling of data from the 2013 Global Burden of Disease Study suggests that at least 17 million people are currently infected with O. volvulus 1 . An estimated 198 million people live in areas where there is potential for transmission of the parasite, although this number may increase as the mapping of areas of low transmission is finalized 2 . The disease is also known as river blindness because blackflies breed in and bite near fast-flowing rivers, and because the most devastating sequela is irreversible loss of vision. High infection load, measured by the density of microfilariae (the larval progeny of adult worms) in the skin, is associated both with blindness incidence 3 and excess human mortality, the latter over and above that due to blindness 4,5 . In addition to ocular sequelae, onchocerciasis is also responsible for skin disease and troublesome itching (which disturbs sleep and work patterns). The Global Burden of Disease Study 2015 estimated the disability-adjusted life years (DALYs) due to onchocerciasis as 1,136,000 in 2015 (a 21% decrease since 2005) 6 . More recently, the term river epilepsy has been used to highlight the association between onchocerciasis and nodding syndrome (a condition in the epilepsy spectrum) 7 . The burden of onchocerciasis-associated epilepsy for 2015 was estimated as circa 13% of the total years lost due to disability (YLDs) attributable to onchocerciasis and 10% of those attributable to epilepsy 8 .
Currently, the mainstay of onchocerciasis control is through mass drug administration (MDA) of the microfilaricidal drug ivermectin (Mectizan®), donated by Merck & Co. Inc. to endemic countries through the Mectizan Donation Program 9 . Ivermectin MDA (mostly of annual frequency in SSA) started in the late 1980's, and great strides in reducing morbidity have been made 10 . Although questions were raised concerning the feasibility of eradicability based on ivermectin MDA alone 11-13 , studies in some foci of Mali and Senegal (in the western extension of the Onchocerciasis Control Programme in West Africa, OCP), indicated that local elimination may be achieved after 15-17 years of ivermectin MDA 14, 15 . Based on this, in 2010, the African Programme for Onchocerciasis Control (APOC) shifted its goals from elimination of the disease as a public health problem (EPHP), to elimination of transmission (EOT) 16 . This shift necessitates a drastic geographical extension of treatment. Whilst for EPHP, mesoendemic and hyperendemic areas had been prioritized for ivermectin MDA, EOT at a Pan-African scale requires that treatment be distributed also in hypoendemic areas. This poses challenges, particularly where loiasis (a filariasis caused by Loa loa) is co-endemic due to severe adverse events, including fatalities, that may result from microfilaricidal treatment of individuals heavily infected with L. loa 17 . In onchocerciasis, the original definition of endemicity levels comprises three categories: i) hypoendemic (microfilarial prevalence <30-35%), ii) mesoendemic (prevalence between 30-35% and 60%), and iii) hyperendemic (≥60%) 18 ; EOT should be achieved in all three. A microfilarial prevalence ≥80% has also been used to indicate holoendemicity 19 .
EOT is formally defined as a reduction to zero in the incidence of infection (rate at which new cases arise) 20 . However, since in macroparasite epidemiology the number of parasites in the population is more relevant than the number of cases, the definition of EOT used here is the absence of adult worms and larval stages (in humans and vectors) after cessation of interventions 21 . Onchocerciasis is in the fortunate position that ivermectin reduces: i) morbidity (mainly caused by microfilariae), ii) microfilarial prevalent cases and microfilarial load, and iii) transmission to vectors (microfilariae are the stages infective to blackflies). This is achieved by a combination of ivermectin's microfilaricidal effect, temporary embryostatic effect on adult female worms (macrofilariae) 22 , and irreversible effects on female worm fecundity and/or survival 23, 24 . Given the disease-and transmission-curtailing benefits of ivermectin MDA, the 2012 World Health Organization (WHO) roadmap to accelerate progress in combating neglected tropical diseases (NTDs) proposed that onchocerciasis be eliminated in selected African countries by 2020 25 . The Joint Action Forum of APOC reformulated this goal to EOT in 80% of endemic African countries by 2025 26 .
To help evaluate progress towards these goals, the developers of two mathematical models of onchocerciasis transmission dynamics and control (EPIONCHO and ONCHOSIM) have joined forces under the umbrella of the Bill & Melinda Gates Foundation-funded NTD Modelling Consortium. The modelling groups, based at Imperial College London (ICL), UK, and Erasmus Medical Center (EMC), The Netherlands, along with multi-disciplinary collaborators have led the recent onchocerciasis work. Firstly, a comparison of modelling assumptions and resulting outputs was conducted 27 , highlighting the need to present and discuss the models jointly 28 , and modify some key assumptions crucial to fitting the microfilarial prevalence trends observed in the elimination studies of Mali and Senegal 29 . A policy paper followed, discussing the role of intervention strategies other than annual ivermectin MDA to achieve elimination in SSA 30 . A further understanding of critical uncertainties led to a paper discussing these in light of data needs 31 . Due to knowledge gaps surrounding the processes regulating parasite establishment and fecundity of O. volvulus 32-34 , the magnitude of exposure heterogeneity and its interaction with such regulatory processes 31 , and the impact of treatment on population biology parameters, including the development of acquired immunity 35 , the models have contrasting underlying assumptions leading to differences in model predictions 29, 30 . Despite these differences, the models generally agree on the treatment strategies required to achieve EOT.
Moving towards the post-2020 goals, new NTD goals have been proposed by the WHO for 2030 within the framework of a consultation process. Table 1 summarizes the current (2020) and proposed (2030) goals for onchocerciasis, the scenarios in which both models agree that EOT is technically feasible with current interventions, the alternative treatment strategies (ATS 36,37 ) required when current ones are not sufficient, the suitability of available tools for evaluating EOT, the principal uncertainties driving differences in model outputs, and the biggest risks associated with the proposed 2030 goals.
Insights gained from quantitative and mathematical modelling analyses
1) Initial model comparison: Predictions from EPIONCHO and ONCHOSIM were compared over a range of baseline endemicities and treatment scenarios. In particular, comparisons were made on: 1) microfilarial prevalence and intensity during 25 years of (annual or biannual) MDA with ivermectin; 2) required duration of treatment to bring microfilarial prevalence below a provisional operational threshold for treatment interruption (pOTTIS) of 1.4% 16,38 ; and 3) required duration to drive the parasite population to local elimination (defined by stochastic fade-out in ONCHOSIM and passing the transmission breakpoint in EPIONCHO). In mesoendemic areas, the models predicted that the provisional operational prevalence threshold could be reached with annual MDA. In highly hyperendemic areas, the models indicated that annual MDA would be insufficient. In lower endemicity settings, ONCHOSIM predicted that the time needed to reach 1.4% microfilarial prevalence would be longer than that required to reach local elimination; the opposite was true for higher endemicity settings. In EPIONCHO, the pOTTIS was reached consistently sooner than the breakpoint 27 .
2) Modelling elimination studies: Based on the initial model comparison, technical refinements were implemented (e.g. age-dependent adult worm mortality in EPIONCHO). EPIONCHO and ONCHOSIM projections were tested against microfilarial prevalence data from the two foci in Mali and Senegal where the observed prevalence had been brought to zero in 2007-2009 after 15-17 years of ivermectin MDA only 14,15 . Model projections were trained using longitudinal (microfilarial prevalence) data from 27 communities in two transmission foci, incorporating programmatic information (treatment frequency, duration and coverage), and evaluating whether the projected outcome was elimination (local parasite extinction) or resurgence. The epidemiological trends during MDA were captured by both models but resurgence was predicted by EPIONCHO in some communities of the River Gambia focus in Senegal with the highest (inferred) annual biting rates (no. vector bites/person/year) and associated pre-intervention endemicities (Figure 1 and Figure 2) 29 . Resurgence was never predicted by ONCHOSIM.
Table 1. Summary of modelling insights and challenges for reaching the World Health Organization (WHO) 2030 goals for onchocerciasis.

Current WHO Goal (2020 Goal)
Elimination of transmission (EOT) by 2020 in Latin America, Yemen, selected African countries.
Proposed New WHO Goal (2030 Goal)
Verified EOT in 10 countries; stopped mass drug administration (MDA) in at least one focus in 34 countries; stopped MDA in ≥ 25%, ≥50%, ≥75% and 100% of population in >16, >14, >12, >10 countries, respectively.
Is the new target technically feasible under the current intervention strategy?
EOT feasible in areas with low or moderate endemicity, where MDA has been ongoing for several years; uncertain for hyper-and holoendemic areas or where MDA has not yet started (distribution of pre-intervention prevalence in different countries will determine feasibility of stopping MDA goals).
If not, what is required to achieve the target? (updated strategy, use of new tools, etc.)
Hyper-and holoendemic areas: switch to biannual or quarterly MDA, complementary vector control; areas without loiasis not previously treated: biannual MDA, quarterly MDA, moxidectin. Areas with loiasis not previously treated: Ta(N)T*, vector control, TaT** with anti-Wolbachia therapies.
Are current tools able to reliably measure the target? 3) Alternative treatment strategies: ONCHOSIM and the refined version of EPIONCHO 29 were used to simulate trends in microfilarial prevalence for 80 different settings. These settings were defined by their baseline endemicity and past programmatic scenario (frequency and coverage of MDA) and future treatment scenarios defined by the frequency (annual, biannual, or quarterly), with or without vector control. Each strategy was assessed whether it eventually led to elimination 30 . Both models predicted that in areas with 40%-50% precontrol microfilarial prevalence and ≥10 years of annual MDA, elimination may be achieved within a further 7 years without changing strategy. For areas with 70%-80% pre-control microfilarial prevalence, both annual and biannual MDA were predicted by ONCHOSIM (but not by EPIONCHO) to be sufficient strategies to reach elimination by 2025. The likelihood that elimination will be reached thus depends on precontrol endemicity (i.e. transmission intensity), duration and frequency of past MDA, and the strategy implemented from now until 2025. Biannual or quarterly MDA will accelerate progress toward elimination but it cannot be guaranteed by 2025 in high-endemicity areas. In such areas, MDA plus concomitant vector control would be useful 30 .
4) Resilience to interventions:
Both models incorporate microfilarial density-dependent establishment of O. volvulus L1 larvae within savannah species of S. damnosum sensu lato (i.e. S. damnosum sensu stricto / S. sirbanum) 28 . However, only EPIONCHO assumes transmission intensity-dependent parasite establishment within humans 31, 32 . An individual-based, stochastic version of EPIONCHO (EPIONCHO-IBM) was developed to explore the interaction between individual heterogeneity in exposure to infection (via vector bites) and parasite establishment within humans (greater at lower transmission intensities and vice versa). Transmission intensity is measured by the annual rate of human exposure to infective (L3) larvae (no. L3 larvae/person/year). EPIONCHO-IBM was fitted (using Latin hypercube sampling) to matched (savannah) pre-intervention microfilarial prevalence, load and annual biting rate (ABR) data (extending Figure 1a range). Density dependence in parasite establishment within humans was estimated for different levels of (fixed) exposure heterogeneity (Figure 3 ) 31 . The interaction between overdispersion in exposure to blackfly bites (parameter k E ) and densitydependent parasite establishment stabilizes low (hypoendemic) prevalence, but accentuates resilience to MDA, explaining the lower EOT probabilities predicted by EPIONCHO.
In view of (1)-(4) above, Box 1 summarizes the insights gained thus far and their implications for post-2020 goals.
Box 1. Lessons learned from onchocerciasis modelling and implications for the post-2020 goals.
• Elimination of transmission (EOT) prospects depend strongly on local transmission conditions. The required duration of interventions increases and the probability of reaching EOT decreases with higher baseline endemicity, higher vector biting rates, and stronger aggregation of infection in the human host population (due to exposure heterogeneity) 27,29,31 .
• Programme effectiveness is important. Program duration increases, and probability of EOT decreases, with lower coverage and higher systematic non-adherence 46,47 .
• Current strategies may not be sufficient. Implementation of current strategies (annual mass drug administration [MDA], with at least 65% coverage) would lead to long timelines to EOT in some countries. Even with the more optimistic model (ONCHOSIM), some countries would need to continue their programs until 2045 48 .
• Alternative treatment strategies (ATS) to accelerate EOT. a) Improve MDA coverage (to 80%); b) minimize systematic non-adherence; c) increase MDA frequency (to biannual or quarterly) 30,46 ; d) use more efficacious treatment regimens (moxidectin 49 , anti-Wolbachia drugs 50 ; e) where feasible, implement additional vector control (e.g. groundbased larviciding of vector breeding sites; slash-and-clear of vegetation substrates of vector immature stages; adult blackfly traps) 30,51,52 .
• Key uncertainties. EPIONCHO and ONCHOSIM model outputs diverge concerning the feasibility of EOT in hyperendemic areas (60-80% microfilarial prevalence) with current or thus far modelled ATS strategies 30 , reflecting uncertainty about key biological processes (e.g. those regulating parasite establishment within humans and exposure heterogeneity) 31 . For holoendemic areas (80% prevalence and above), both models agree that current strategies will be insufficient.
• Expansion of interventions into (currently untreated) hypoendemic areas.
Work is ongoing to define efficient sampling strategies for delineation of new (hypoendemic) treatment areas, based on serology-based start-MDA thresholds. This is problematic in areas where loiasis is coendemic, as ivermectin treatment can be fatal in individuals with high Loa loa microfilaraemia 17 . A test-(for loiasis)-andnot-treat (if microfilaraemia is above dangerous thresholds) strategy can be used 39 . Because the proportion of people with heavy L. loa microfilaraemia is often small (~2-4%), models predict that this strategy could lead to EOT if screening and treatment coverage/adherence are high.
Practical implications of the currently proposed EOT goals
Measuring the target 1) Definition of EOT according to the models. EOT is modelled as absence of parasites in humans and flies 50 years after treatment cessation 21 . The probability of EOT is the proportion of runs out of the total number of simulations in which EOT is achieved. In practice, evaluating whether foci are in track to achieve EOT depends on the ability of current (and novel) diagnostics to measure accurately interruption of transmission. Indicators of exposure in children and fly samples have been suggested for such evaluation.
2) Diagnostics. The WHO guidelines for verification of EOT require <0.1% IgG4 antibody seropositivity to the Ov-16 O. volvulus antigen in children younger than 10 years, and <0.05% positivity by pool screen PCR in at least 6,000 wild-caught flies (heads only) 53 . Models suggest that the magnitude of the serological thresholds will depend on: i) local transmission conditions (e.g., the higher the ABR, the lower the thresholds will need to be and vice versa; this also applies to entomological indicators); ii) age-dependent exposure patterns (e.g. the younger the age at which exposure to transmission starts, and the greater the rate of increase with age, the younger the age group for which serological monitoring will be informative and vice versa; see below for sampling implications); iii) history of previous control interventions; iv) heterogeneity concerning the above within evaluation areas; v) spatial scale at which EOT is assessed; vi) desired positive predictive value (PPV, the probability of elimination below the said threshold) of EOT; vii) assumptions on parasite population regulation; and viii) diagnostic performance of the tests 54 .
3) Sources of uncertainty in current threshold estimates.
A key uncertainty is the operation of regulatory processes upon within-human parasite establishment (e.g. due to acquisition of anti-L3 immunity in areas of intense transmission). Omitting such processes (ONCHOSIM) leads to higher (more lenient) thresholds; including them (EPIONCHO) results in lower (more stringent) thresholds. Adjusting modelling results by the diagnostic performance of the tests changes the apparent magnitude of the thresholds. Diagnostic performance (e.g. sensitivity/specificity) of current tests is another key uncertainty 54 .
4) Sampling implications.
Modelling indicates that the childhood age group most informative for Ov-16 serology will depend on the age-specific patterns of exposure that prevail in the various foci. In areas where exposure increases quickly from birth, the 0-9yr age group may be suitable. In areas where exposure increases more slowly, the 5-14yr age group will be more informative.
Deciding which age group to choose can be aided by inspecting baseline infection age profiles 55 .
Timeline to achieve the target 1) Technical feasibility • General considerations. Elimination prospects depend strongly on local transmission conditions (Box 1). The required strategy intensifies (e.g. the duration and/or frequency of interventions increases, and the need for complementary/ATS increases) with higher baseline endemicity, higher ABRs, and stronger aggregation of infection in the human population (acting as a core group maintaining transmission) 13,27,31 .
• Moderate transmission settings. EOT can be achieved with annual or biannual MDA if coverage and adherence are high (in the models, 'enhanced' coverage is defined as 80% therapeutic coverage and 1% systematic non-adherence).
• Hyper-and holoendemic settings. The model-predicted feasibility of EOT is more uncertain, even when modelling the ATS considered thus far (increased coverage and frequency, vector control 30 ). The epidemiological impact of other ATS (e.g. moxidectin 49 , macrofilaricides 50,56 ) needs to be evaluated.
2) Operational feasibility • General considerations. Multiple intervention strategies will need to be combined in an optimal way to achieve continent-wide EOT. Further research is needed to identify such strategies according to epidemiological features 30 .
• Role of epidemiology/transmission ecology. The choice of intervention strategies will depend on epidemiological and ecological features. Hyperendemic areas would benefit from biannual/quarterly MDA if feasible to implement (non-loiasis co-endemic 57,58 ; no sub-optimal responses to ivermectin 59 ); highly hyperendemic/holoendemic areas will likely need optimized ATS, including macrofilaricidal interventions 36, 37 . The optimal ATS suite (vector control, moxidectin, anti-Wolbachia therapies, macrofilaricides) needs to be determined according to setting. Programs need to expand into currently untreated hypoendemic areas, including untreated loiasis co-endemic areas 58 (see above for test-and(not)treat strategies 39 ).
• Programmatic features. Achieving and maintaining high coverage and adherence over each MDA round is paramount, especially in highly endemic settings. Long-term treatment can suffer from programme, communities and donor fatigue. Weak EOT programs need strengthening 60 .
3) Ability to sustain achievement of the goal • Dynamics of resurgence. The dynamics of resurgence according to setting need further investigation 29 , as well as the factors leading to resurgence, e.g. residual (endogenous) infections or re-introduction of (allogenous) infections from surrounding areas through migration of humans and/or flies. Investigation of these dynamics will inform post-treatment and post-elimination surveillance protocols 53 .
4) Considerations of cost
• Health and economic benefits. Achieving EOT in Africa would lead to substantial health and economic benefits, reducing the needs for health workforce and outpatient services 61 . ATS needs and cost-effectiveness remain to be captured 37,49,62,63 .
• Logistic and cost implications. Striving for Pan-African EOT has considerable logistic and cost implications, due to required programme expansion into currently untreated areas, prospects of enhanced or more frequent MDA or ATS, and improved (post-treatment and post-EOT) surveillance. The increased costs should be weighed against shorter programme duration and higher probability of success. Costs per year are higher for biannual than for annual MDA, but costs do not simply double 38, 63 . Annual moxidectin may be more costeffective than biannual ivermectin, should this drug be donated 49 . Economic analyses of moxidectin, anti-Wolbachia therapies, macrofilaricides, and vector control (ground larviciding, slash-and-clear, adult fly traps) need to be conducted. The costs of testand-not-treat for loiasis co-endemic areas were recently assessed in Cameroon 62 .
Risks faced by treatment programs that need to be mitigated to achieve EOT
Some programs, particularly those in areas affected by conflict are more likely to under-perform, suffer from interrupted MDA schedules, or be delayed in starting and up-scaling implementation. Internal population displacement as well as mass migration to other countries could jeopardize progress towards EOT. Weak programs/health systems need to be identified, supported and strengthened 60 . Movement of infected individuals (between endemic communities within countries, and betweencountries) due to traditional cultural and trade patterns may lead to re-introduction of infection in areas achieving EOT. Risk of declining drug efficacy following multiple rounds of MDA/existence of sub-optimal responses to treatment should be monitored 59,64 . Low coverage and systematic nonadherence may lead to persistent transmission, particularly (but not exclusively) in loiasis co-endemic areas 65 . Factors associated with non-compliance need further investigation. Reported coverage levels are generally higher than true coverage, possibly because coverage has been a primary indicator of program effectiveness. Population denominators may not be correct due to lack of updated censuses. Reported coverages are aggregated by district, but disaggregate data are needed to evaluate and correct coverage heterogeneity. Table 2 outlines the priority modelling questions for further research that were elaborated in discussion with the WHO.
Modelling priorities to support goals in the 2030 horizon and beyond
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3. Both models predict that elimination of transmission is possible by the WHO proposed dates in areas that have already started MDA and where coverage is at least 75%, which is higher than the currently accepted 65% coverage. Hyperendemic regions and those regions that have only just recently started or have not started will require biannual to quarterly MDA to keep to this schedule. Areas coendemic with loiasis could also achieve elimination using test-and-not-treat and alternative strategies, e.g. antitreatments. However, the latter will need newer analysis once results from treatment in such Wolbachia areas become available.
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The analysis of the results from both models highlighted the need for greater research into diagnostics of onchocerciasis infections and the biology of infection, especially in how it relates to microfilariae prevalence and transmission rates. Both areas are sources of uncertainty in the modelling. Nevertheless, the authors provided straight forward conclusions as to the practical implications of the current elimination goals and timeline to achieving them, and provide a list of priorities discussed with the WHO for prioritizing modelling in support of the goals by 2030 and beyond.
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